HAEMONETICS CORP SEC Filings

Haemonetics EVP and COO Frank Chan received an equity award and had shares withheld for taxes. On May 15, 2026, he was granted 27,535 restricted stock units (RSUs) under the company’s long-term incentive plan. Each RSU represents a right to receive one share of common stock when it vests.

The RSUs vest over three years, with 40% vesting on the first anniversary of the grant date, another 40% on the second anniversary, and the remaining 20% on the third anniversary. On the same date, 546 shares were disposed of at $56.29 per share to satisfy tax obligations related to vesting of previously granted RSUs, rather than through an open-market sale.

After these transactions, Chan directly owned 32,936 shares of Haemonetics common stock. This figure includes unvested RSUs and shares acquired through the Haemonetics Corporation 2007 Employee Stock Purchase Plan, including 139 shares bought on October 31, 2025 and 119 shares bought on April 30, 2026.

Haemonetics Corporation EVP and CFO James DArecca reported a new equity compensation grant. He received 29,312 shares of common stock in the form of restricted stock units (RSUs) at no cash cost, increasing his direct equity-based position.

In a related transaction, 2,505 shares were withheld at a market price of $56.29 per share to cover tax obligations tied to RSU vesting, which is not an open-market sale. After these transactions, he directly holds 54,444 shares, a figure that includes previously reported unvested RSUs.

The RSU award was granted under Haemonetics’ Amended and Restated 2019 Long-Term Incentive Compensation Plan. The units vest in three annual installments, with 40% vesting on each of the first two anniversaries of the grant date and the remaining 20% vesting on the third anniversary. Each RSU converts into one share of common stock upon vesting.

Haemonetics Corp VP and Chief Accounting Officer Maryanne Maunsell Farris received a grant of 2,220 restricted stock units, each representing one share of common stock vesting in three equal annual installments. In connection with RSU vesting, 197 shares were withheld to cover tax obligations, leaving her with 6,501 directly held shares, including unvested RSUs.

Haemonetics EVP and Chief Commercial Officer Roy Galvin reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. He received a grant of 27,535 shares of common stock in the form of RSUs under the company’s long-term incentive plan. These RSUs vest over three years, with 40% vesting on each of the first two anniversaries of the grant date and 20% on the third anniversary. On the same date, 879 shares valued at $56.29 per share were withheld to cover tax obligations tied to vesting RSUs, rather than sold on the open market. Following these transactions, he directly holds 39,882 shares of common stock, a figure that includes unvested RSUs previously reported and 415 shares acquired through the Haemonetics Corporation 2007 Employee Stock Purchase Plan.

Haemonetics Corp senior vice president of human resources Laurie A. Miller reported routine equity compensation activity involving company common stock. She received a grant of 13,323 shares valued at zero cost to her, reflecting the vesting or award of restricted stock units under the company’s long-term incentive plan.

In a related move, 948 shares at $56.29 each were withheld to cover tax obligations tied to the RSU vesting, a non-market transaction rather than an open-market sale. After these transactions, she directly holds 41,300 shares of Haemonetics common stock.

Haemonetics Corp President & CEO Christopher Simon reported compensation-related equity activity. He received an award of 78,344 shares of common stock in the form of restricted stock units that vest over three years. On the same date, 9,681 shares were withheld to cover tax obligations tied to previously vesting RSUs, and his reported direct holdings after these transactions were in the hundreds of thousands of shares.

North Peak group and related persons filed an amended Schedule 13G/A reporting ownership of 5 percent or less of Haemonetics Corp. The filing is a joint statement by North Peak Capital Management, North Peak Capital GP, several North Peak funds, and Jeremy S. Kahan and Michael K. Kahan.

The cover lists the class as Common stock, $0.01 par value with CUSIP 405024100. The filing cites joint filing arrangements and states each Reporting Person disclaims beneficial ownership beyond the group description; signatures are dated 05/13/2026.

Haemonetics reported fourth quarter and fiscal 2026 results and issued fiscal 2027 guidance. Fourth quarter revenue was $346.4 million, up 4.8%, while fiscal 2026 revenue was $1.33 billion, down 2.0% from fiscal 2025.

Due mainly to a $77.2 million impairment related to Attune Medical and other charges, the company posted a fourth quarter net loss of $20.1 million, or $(0.44) per diluted share, versus earnings of $1.17 a year earlier. Adjusted diluted EPS for the quarter rose to $1.29, and fiscal 2026 adjusted diluted EPS was $4.96.

Operating cash flow for fiscal 2026 was $293.2 million and free cash flow was $209.9 million. In the fourth quarter, the company repurchased 1.58 million shares for $100 million, leaving $325 million under its authorization. For fiscal 2027, Haemonetics guides to 4–7% reported revenue growth, 3–6% organic revenue growth and about 80% free cash flow conversion.

Haemonetics EVP and CFO James DArecca reported a small tax-related share disposition. On May 1, 2026, 655 shares of Haemonetics common stock were withheld at $59.26 per share to cover tax obligations from vesting restricted stock units. This was not an open-market sale. After the withholding, DArecca directly owned 27,637 shares, which includes previously reported unvested RSUs.